Teva confirms September PDUFA date for fremanezumab
Teva confirmed the FDA has extended the goal date of the BLA for fremanezumab, an investigational therapy for preventive treatment of migraine. The PDUFA action date for fremanezumab is set for Sept.16, 2018. There are no additional data requests from the FDA. May 23, 2018